Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study Journal Article

  

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1985 1984 1983 1982 1981 1980 1979 1978 1977 1976 1975 1974 1973 1972 1971 1970 1969 1968 1967 1966 1965 1964 1963 1962 1961 1960 1959 1958 1957 1956 1955 1954 1953 1952 1951 1950 1949 1948 1947 1946 1945 1944 1943 1942 1941 1940 1939 1938 1937 1936 1935 1934 1933 1932 1931 1930 1929 1928 1927 1926 1925 1924 1923 1922 1921 1920 1919 1918 1917 1916 1915 1914 1913 1912 1911 1910 1909 1908 1907 1906 1905 1904 1903 1902 1901 1900 1899 1898 1897 1896 1895 1894 1893 1892 1891 1890 1889 1888 1887 1886 1885 1884 1883 1882 1881 1880 1879 1878 1877 1876 1875 1874 1873 1872 1871 1870 1869 1868 1867 1866 1865 1864 1863 1862 1861 1860 1859 1858 1857 1856 1855 1854 1853 1852 1851 1850

Authors:	Zhou, L. T.; Singh, P.; Crossman, D.; Richman, J.; Trainor, P.; Cheng, C. D.; Wang, X. X.; Sharafeldin, N.; Hageman, L.; Sheikh, M.; Richard, M. A.; Friedman, D. N.; Neglia, J. P.; Wang, Z. M.; Hudson, M. M.; Armenian, S. H.; Hawkins, D.; Bhatia, R.; Landier, W.; Bhatia, S.
Article Title:	Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study
Abstract:	<p>PURPOSEThere is emerging evidence that germline pathogenic/likely pathogenic (P/LP) mutations in cancer predisposition genes (CPGs) increase the risk of subsequent neoplasms (SNs) in childhood cancer survivors. However, clinical application of this observation is hampered by the lack of knowledge regarding subpopulations at risk for SNs who could potentially benefit from genetic screening.PATIENTS AND METHODSWhole-exome sequencing was performed using germline DNA from 499 survivors with SNs (cases) and 625 survivors without (matched controls) in a Children's Oncology Group study. Using conditional logistic regression, we estimated demographic/clinical/therapeutic characteristics and P/LP mutations associated with SN risk. We then randomly partitioned the case-control data set using a 60/40 split to create training and test data, respectively, and developed a clinical risk classifier. Model performance and its improvement with addition of P/LP mutation status was evaluated on the test data using the area under the receiver operating curve (AUC).RESULTSWe found a 4.26-fold higher odds of SNs among P/LP mutation carriers (95% CI, 2.36 to 7.69). The clinical risk classifier (including sex, primary cancer type and year of diagnosis, exposure to radiation and platinum compounds, and length of follow-up) showed a significant performance improvement with the addition of P/LP mutation status, and P/LP x platinum and P/LP x radiation interactions (AUC increased from 0.79 to 0.82, P = .014). Using the clinical risk classifier, we classified survivors at low risk (22%) and moderate-to-high risk (78%) of developing SNs. Overall, 86.4% of the survivors with any P/LP mutations, and all TP53 and RB1 mutation carriers were partitioned into the moderate-to-high risk group.CONCLUSIONThese findings provide a risk-based approach for identifying childhood cancer survivors who could be referred for genetic testing, informing surveillance strategies on the basis of refined risk classification.</p>
Keywords:	platinum; lung-cancer; dna-repair; 5-year survivors; index; risk-assessment
Journal Title:	Journal of Clinical Oncology
Volume:	43
Issue:	27
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2025-09-20
Language:	English
ACCESSION:	WOS:001574048800015
DOI:	10.1200/jco-25-00542
PROVIDER:	wos
Notes:	Article -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/229005